Skip to main content
Helmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logo
Marcus Conrad erhält Paul-Martini-Preis
Paul-Martini-Stiftung | Thomas Boehm

Paul Martini Prize for Marcus Conrad

Awards & Grants, Molecular Targets and Therapeutics, MCD,

For his discoveries in the field of ferroptosis – a specific form of programmed cell death that opens up new perspectives for the development of drugs in cancer therapy and organ transplantation – Prof. Marcus Conrad has been awarded the Paul Martini Prize. The prestigious award, presented annually by the Paul Martini Foundation in Berlin, honors outstanding achievements in clinical and therapeutic drug research and is endowed with €50,000.

Learn more about this recoginition in our news in German. 

Related News

Apoptosis process in a cell
Molecular Targets and Therapeutics, MCD,

Ferroptosis: Controlling Life or Death of Cells

Cell death is indispensable to life, as it ensures the removal of damaged or unnecessary cells. Among the many ways a cell can die, ferroptosis is a unique and regulated form of cell death. This process plays a significant role in the pathogenesis of…

read more
Marcus Conrad
Awards & Grants, Molecular Targets and Therapeutics, MCD,

Award-Winning Ferroptosis Expert Marcus Conrad

Prof. Marcus Conrad, Director of the Institute of Metabolism and Cell Death at Helmholtz Munich, was awarded the ECDO Honorary Award 2024 for his pioneering research on ferroptosis. He has been a Professor at the Technical University of Munich (TUM)…

read more
Marcus Conrad Galenus-Preis
Awards & Grants, Molecular Targets and Therapeutics, MCD,

Marcus Conrad Wins Galenus Award for Ferroptosis Research

Prof. Marcus Conrad, Director at the Institute of Metabolism and Cell Death at Helmholtz Munich, has been awarded the Galenus-von-Pergamon Award in the category of Basic Research. The honor recognizes his pioneering contributions to the field of…

read more
FSP1 condensates in green induced by icFSP1 surrounding a blue nucleus
New Research Findings, MCD,

New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis. Ferroptosis is characterized by the iron-dependent oxidative destruction of…

read more